Komori
TAUNS Laboratories (197A) · TargetAdvanced

Expansion into non-infectious disease areas, including chronic diseases, cancer and kidney disease

First written in FY2024. 6 of 8 entries say "Advanced", first in 2026-07-08. Latest entry: FY2026.

8entries
3years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20242024: 120242025: 020252026: 72026
Same theme, other companies
Expansion into Testing Businesses for Chronic Diseases, Cancer, and Kidney Disease Beyond Infectious DiseasesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「In parallel with developing the data and AI infrastructure supporting these initiatives, we are taking concrete steps toward entering the chronic disease field.」

    The planned entry into the chronic disease field was described as having moved from a statement of policy to a concrete implementation phase involving the development of data and AI infrastructure.
  3. FY2024First statedAnnual report

    「We are pursuing expansion into the chronic disease field, beginning with Accuread Zinc, which diagnoses zinc deficiency by measuring zinc concentrations in the blood.」

    Examples cited include companion diagnostics for cancer, liquid biopsy for cancer, kidney disease testing, and periodontal disease testing.
Moved together

"IP and Technology Partnership Investments Toward the 10-Year Business Vision" moved the same way as this thread, in the same document, in 5 of its 8 moves.

522222★123456
  1. ★This thread
  2. 1IP and Technology Partnership Investments Toward the 10-Year Business Vision5×
  3. 2High-sensitivity, multi-analyte, quantitative POCT enabled by D-IA2×
  4. 3Development of New Core Technologies and an Inspection Platform2×
  5. 4Overseas Expansion Through Distributor Networks, Overseas-Market Products and High-Value-Added Products2×
  6. 5Expansion of Sales Channels Through Collaboration with Sales Representatives, Agencies and Pharmaceutical Companies2×
  7. 6Stable, Sustained Dividends Based on a Payout Ratio of Approximately 30%2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet. It last moved in the Business Alliances of 2026-08-18: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expansion into non-infectious disease areas, including chronic diseases, cancer and kidney disease | TAUNS Laboratories,Inc. (197A) | Komori